Skip to Content

Guardant Health Inc GH

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Guardant Health Gets Going With Promising Pipeline, Long-Term Growth on Track After Decent Q3

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

No-moat Guardant Health reported robust growth and made good progress on pipeline initiatives in the third quarter, reinforcing our positive moat trend rating. Considering the long-term opportunity in liquid biopsy, we are not concerned about slightly higher-than-expected operating costs in the near term, and our $91 fair value estimate remains unchanged.

Read Full Analysis

Company Profile

Business Description

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.

Contact
505 Penobscot Drive
Redwood City, CA, 94063
T +1 855 698-8887
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Speculative Growth
Employees 864